News Image

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Provided By PR Newswire

Last update: Nov 18, 2025

The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively, that of the Aramchol free acid 300mg tablets

Read more at prnewswire.com

GALMED PHARMACEUTICALS LTD

NASDAQ:GLMD (12/1/2025, 7:38:42 PM)

After market: 0.9399 -0.03 (-3.53%)

0.9743

+0.03 (+3.66%)



Find more stocks in the Stock Screener

GLMD Latest News and Analysis

Follow ChartMill for more